Last reviewed · How we verify
NCT06779474
Laparoscopic Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) for Colorectal Liver Metastases (CRLM)
trial testing Laparoscopic ALPPS in Colorectal Liver Metastases in 30 participants. Not yet recruiting.
1 May 2030
Quick facts
| Lead sponsor | Yanhong Deng |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 May 2025 |
| Primary completion | 1 May 2030 |
| Estimated completion | 1 May 2030 |
| Sites | 1 location across China |
Drugs / interventions tested
- Laparoscopic ALPPS
Conditions studied
- Colorectal Liver Metastases — all drugs for Colorectal Liver Metastases →
Sponsor
Yanhong Deng — full company profile →
Who can join
Adults 18 to 75, any sex, with Colorectal Liver Metastases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a procedure used for patients with initially unresectable colorectal liver metastases (CRLM). However, the procedure has been reported to be associated with high morbidity and mortality. Laparoscopic ALPPS has recently been reported as a minimally invasive technique that reduces perioperative risks. This study aimed to assess the safety and feasibility of full laparoscopic ALPPS in patients with CRLM.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06779474
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Liver Metastases
Currently open trials in the same condition.
- NCT06501482 — Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI · Phase 3 · recruiting
- NCT07117435 — Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in · Phase 1 · recruiting
- NCT06638502 — Safety of HRX215 in Patients After Minor and Major Liver Resection · Phase 1, PHASE2 · recruiting
- NCT05265169 — Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM) · NA · recruiting
Other Yanhong Deng trials
Trials by the same sponsor.
- NCT05360277 — Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer · Phase 2 · recruiting
- NCT05427669 — Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD) · Phase 3 · not yet recruiting
- NCT06898359 — Role of Gut Microbiota in Neoadjuvant Radioimmunotherapy for MSS, Locally Advanced Rectal Cancer · completed
- NCT05450029 — Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer · Phase 2 · recruiting
- NCT04230187 — Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06779474 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yanhong Deng
- Last refreshed: 17 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06779474.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing